Masimo Corporation (MASI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Masimo Corporation (MASI) trades at $179.95 with AI Score 55/100 (Grade B). Masimo Corporation develops and markets noninvasive patient monitoring technologies and hospital automation solutions. Market cap: $9.42B, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 9, 2026MASI stock analysis for 2026: Analysts have set a consensus price target of $180.00 for Masimo Corporation, suggesting 0.0% upside from the current price of $179.95. The AI MoonshotScore is 55/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MASI: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Masimo Corporation (MASI) Healthcare & Pipeline Overview
Masimo Corporation is a global leader in noninvasive patient monitoring, offering advanced pulse oximetry and hospital automation solutions. Its signal extraction technology and rainbow SET platform differentiate it within the medical devices sector, addressing the limitations of conventional monitoring and expanding into diverse healthcare settings.
What Is the Investment Thesis for MASI?
Masimo Corporation presents a notable research candidate based on its leadership in noninvasive patient monitoring and its expanding portfolio of hospital automation solutions. The company's proprietary SET and rainbow SET technologies provide a competitive edge, driving adoption in hospitals and other healthcare settings. With a market capitalization of $9.42B and a P/E ratio of 123.1, Masimo's valuation reflects its growth potential. Key catalysts include the continued expansion of its hospital automation platform and the introduction of new monitoring technologies. However, investors should be aware of potential risks such as competition from established medical device companies and regulatory hurdles. Masimo's gross margin of 61.7% indicates strong pricing power and efficient operations.
Based on FMP financials and quantitative analysis
MASI Key Highlights
Market Cap of $9.42B reflects Masimo's significant presence in the medical device industry.
- P/E ratio of 123.1 suggests investors anticipate future earnings growth.
- Gross Margin of 61.7% demonstrates efficient operations and strong pricing power.
- Profit Margin of 4.9% indicates areas for potential improvement in operational efficiency.
- Beta of 1.20 suggests the stock is more volatile than the overall market.
Who Are MASI's Competitors?
MASI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MOH Molina Healthcare, Inc. | $198.04 | -1.56% | $10.3B | 79 |
| BAX Baxter International Inc. | $26.41 | -0.86% | $13.7B | 52 |
| ABVX Abivax S.A. | $117.31 | -2.70% | $8.61B | 76 |
| HSIC Henry Schein, Inc. | $89.29 | +0.07% | $10.2B | 73 |
| ATR AptarGroup, Inc. | $132.96 | +0.02% | $8.49B | 74 |
| AVTR Avantor, Inc. | $13.96 | +4.73% | $9.44B | 53 |
| RGEN Repligen Corporation | $180.29 | +2.23% | $10.2B | 81 |
| BLCO Bausch + Lomb Corporation | $17.20 | -1.43% | $6.14B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MASI's Key Strengths?
Proprietary SET and rainbow SET technologies
- Strong brand reputation
- Integrated hospital automation platform
- Extensive distribution network
What Are MASI's Weaknesses?
High P/E ratio may indicate overvaluation
- Profit margin could be improved
- Reliance on hospital spending
- Competition from established medical device companies
What Could Drive MASI Stock Higher?
Launch of new monitoring technologies and sensors.
- Expansion of the Hospital Automation platform into new hospitals and healthcare systems.
- Increasing adoption of Masimo's products in emerging markets.
- Strategic partnerships with other healthcare technology companies.
What Are the Key Risks for MASI?
Rich valuation — a P/E of 123.1 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Competition from established medical device companies.
- Regulatory hurdles and delays in product approvals.
- Economic downturns and reduced hospital spending.
- Patent expirations and potential for generic competition.
- Supply chain disruptions affecting manufacturing and distribution.
What Are the Growth Opportunities for MASI?
- Expansion of Hospital Automation Platform: Masimo's Hospital Automation platform, including Patient SafetyNet and UniView, offers significant growth potential by integrating patient monitoring data with clinical workflows. Masimo's competitive advantage lies in its ability to seamlessly integrate its monitoring technologies with its automation platform, providing a comprehensive solution for hospitals.
- Penetration of Emerging Markets: Emerging markets represent a significant growth opportunity for Masimo, as healthcare systems in these regions increasingly adopt advanced patient monitoring technologies. The demand for noninvasive monitoring solutions is growing in countries with expanding healthcare infrastructure and rising healthcare expenditure. Masimo can leverage its existing distribution network and OEM partnerships to penetrate these markets and establish a strong presence.
- Development of New Monitoring Technologies: Masimo's commitment to innovation drives the development of new monitoring technologies that address unmet clinical needs. The company's research and development efforts focus on expanding the capabilities of its rainbow SET platform and exploring new applications for its SedLine brain function monitoring technology. The introduction of new monitoring parameters and solutions can drive revenue growth and strengthen Masimo's competitive position.
- Expansion into Consumer Healthcare: Masimo's e-commerce site, masimopersonalhealth.com, provides a platform for expanding into the consumer healthcare market. The demand for personal health monitoring devices is growing, driven by increasing awareness of preventive healthcare and the availability of user-friendly technologies. Masimo can leverage its expertise in noninvasive monitoring to develop and market consumer-focused products, such as wearable pulse oximeters and sleep monitors.
- Strategic Acquisitions and Partnerships: Masimo can pursue strategic acquisitions and partnerships to expand its product portfolio, enter new markets, and enhance its technological capabilities. Acquisitions of companies with complementary technologies or established market positions can accelerate Masimo's growth and strengthen its competitive advantage. Partnerships with healthcare providers and technology companies can facilitate the integration of Masimo's solutions into clinical workflows and expand its reach.
What Are MASI's Competitive Advantages?
- Proprietary Masimo SET and rainbow SET technologies provide a competitive advantage in pulse oximetry.
- Strong brand reputation for accuracy and reliability in patient monitoring.
- Extensive patent portfolio protects its core technologies.
- Integrated hospital automation platform enhances customer value and creates switching costs.
- Established distribution network and OEM partnerships provide broad market access.
What Does MASI Do?
Masimo Corporation, founded in 1989 and headquartered in Irvine, California, is a global medical technology company that develops, manufactures, and markets a range of noninvasive patient monitoring technologies and hospital automation solutions. The company's core innovation lies in its Masimo Signal Extraction Technology (SET) pulse oximetry, designed to overcome the limitations of conventional pulse oximetry by accurately measuring oxygen saturation even during patient motion and low perfusion. This technology forms the basis of many of Masimo's products, which are used in hospitals, emergency medical services, home care, and other healthcare settings. Masimo's product portfolio includes the rainbow SET platform, which expands on the capabilities of SET by noninvasively monitoring multiple hemoglobin parameters, including oxygen saturation, pulse rate, perfusion index, and respiration rate. This platform also enables the monitoring of hemoglobin concentration, carboxyhemoglobin, and methemoglobin. Beyond pulse oximetry, Masimo offers SedLine brain function monitoring technology, capnography and gas monitoring products, O3 regional oximetry for tissue oxygen saturation measurement, and hemodynamic monitoring solutions. The company's Masimo Hospital Automation platform integrates these monitoring technologies with patient surveillance and data management systems, such as Patient SafetyNet and UniView, to improve patient safety and clinical workflows. Masimo distributes its products through a direct sales force, distributors, and original equipment manufacturer (OEM) partners, reaching a diverse customer base across the healthcare spectrum. The company also sells non-medical/consumer products through its e-commerce site, masimopersonalhealth.com.
What Products and Services Does MASI Offer?
- Develops and markets noninvasive patient monitoring technologies.
- Offers Masimo SET pulse oximetry for accurate oxygen saturation measurement.
- Provides Masimo rainbow SET platform for monitoring multiple hemoglobin parameters.
- Offers SedLine brain function monitoring technology.
- Develops capnography and gas monitoring products.
- Provides O3 regional oximetry for tissue oxygen saturation measurement.
- Offers hemodynamic monitoring solutions.
- Develops and markets hospital automation platforms.
How Does MASI Make Money?
- Sells noninvasive patient monitoring devices and sensors.
- Generates revenue from the sale of hospital automation software and services.
- Partners with original equipment manufacturers (OEMs) to integrate its technologies into their products.
- Distributes products through a direct sales force and distributors.
- Sells non-medical/consumer products through its e-commerce site.
What Industry Does MASI Operate In?
Masimo Corporation operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced patient monitoring technologies. The global market for patient monitoring devices is expected to grow, driven by factors such as an aging population, rising prevalence of chronic diseases, and increasing adoption of remote patient monitoring solutions. Masimo competes with established medical device companies, such as Baxter International Inc. (BAX), as well as specialized players in specific monitoring segments. The company's focus on noninvasive technologies and its integrated hospital automation platform position it to capitalize on the growing demand for patient safety and improved clinical workflows.
Who Are MASI's Key Customers?
- Hospitals and acute care facilities
- Emergency medical service providers
- Home care providers
- Long-term care facilities
- Physician offices
- Veterinarians
- Consumers
Forward Outlook
Wall Street analysts project Masimo Corporation revenue of about $1.63B for fiscal 2027, with EPS near $6.00.
Earnings Track Record
Masimo Corporation has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations.
Financial Health
Masimo Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 9.77 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Masimo Corporation stands at 9.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.6%, showing how much profit it generates from its asset base. MASI trades at a trailing price-to-earnings ratio of 123.11, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.8%, the inverse of the P/E and a quick read on earnings relative to price.
Masimo Corporation (MASI) Valuation Context
Valued at $9.42B, MASI is classified as a mid-cap stock. Relative to its peer group, MASI's quantitative score of 55/100 is below the peer average of 71/100.
MASI Revenue & Earnings Trend
In Q2 2026, MASI generated $403.6M in top-line revenue, marking a sequential decrease of 2.2%. The company recorded net income of $57.1M, with diluted EPS of $1.09. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, MASI averaged $0.37 in diluted EPS.
Company Profile
Masimo Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Catherine Szyman. MASI has traded publicly since 2007.
MASI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary SET and rainbow SET technologies
- Strong brand reputation
- Integrated hospital automation platform
- Extensive distribution network
Bear Case
- High P/E ratio may indicate overvaluation
- Profit margin could be improved
- Reliance on hospital spending
- Competition from established medical device companies
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $404M | $57M | $1.09 |
| Q1 2026 | $413M | $68M | $1.27 |
| Q3 2025 | $372M | -$100M | -$1.84 |
| Q2 2025 | $371M | $51M | $0.94 |
Based on FMP financials and quantitative analysis
MASI Latest News
MASI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MASI.
Price Targets
Consensus target: $180.00
MASI MoonshotScore
What does this score mean?
The MoonshotScore rates MASI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Catherine Szyman
CEO
Catherine Szyman is the CEO of Masimo Corporation, leading a workforce of 3600 employees. She has extensive experience in the medical device industry, with a background in engineering and product development. Prior to becoming CEO, she held various leadership positions within Masimo, overseeing research and development, operations, and commercial strategy. Her expertise spans across multiple areas of the business, providing a comprehensive understanding of the company's operations and market dynamics. She is known for her focus on innovation and her commitment to improving patient outcomes through advanced monitoring technologies.
Track Record: Under Catherine Szyman's leadership, Masimo has continued to expand its product portfolio and strengthen its market position in noninvasive patient monitoring. She has overseen the development and launch of new monitoring technologies, as well as the expansion of the company's hospital automation platform. Her strategic decisions have contributed to Masimo's revenue growth and profitability. She has also focused on fostering a culture of innovation and collaboration within the company.
MASI Healthcare Stock FAQ
What does the AI Score mean for MASI?
MASI holds an AI Score of 55/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Masimo Corporation develops and markets noninvasive patient monitoring technologies and hospital automation solutions. Their signal extraction technology (SET) and rainbow SET platforms are used …
What does Masimo Corporation do?
Masimo Corporation is a global medical technology company that specializes in the development, manufacture, and marketing of noninvasive patient monitoring technologies and hospital automation solutions. Its core product is the Masimo Signal Extraction Technology (SET) pulse oximetry, which provides accurate oxygen saturation measurements even during patient motion and low perfusion.
What do analysts say about MASI stock?
Analyst coverage of Masimo Corporation (MASI) typically focuses on the company's growth prospects in the patient monitoring market, its competitive position, and its financial performance. Key valuation metrics such as the P/E ratio and gross margin are closely scrutinized.
What are the main risks for MASI?
Masimo Corporation faces several key risks, including competition from established medical device companies such as Baxter International Inc. (BAX), which offer similar patient monitoring solutions. Regulatory hurdles and delays in product approvals can also impact the company's growth prospects. Economic downturns and reduced hospital spending could negatively affect demand for Masimo's products.
How does Masimo Corporation navigate regulatory approval processes?
Masimo Corporation navigates regulatory approval processes, primarily with the FDA in the United States and similar bodies globally, by maintaining rigorous quality control standards and conducting thorough clinical trials to demonstrate the safety and efficacy of its devices. The company invests significantly in regulatory affairs and employs a team of experts to ensure compliance with all applicable regulations.
How does Masimo Corporation manage patent expiration risks?
Masimo Corporation manages patent expiration risks through a multi-faceted approach that includes continuous innovation, strategic patent filings, and diversification of its product portfolio. The company invests heavily in research and development to create new technologies and improve existing products, ensuring a pipeline of innovations to offset the impact of patent expirations.
What are the key factors to evaluate for MASI?
Masimo Corporation (MASI) holds an AI score of 55/100 (moderate). P/E: 123.1x vs the S&P 500's ~20-25x. Analysts target $180.00 (+0%). Not financial advice.
How frequently does MASI data refresh on this page?
MASI's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MASI's recent stock price performance?
Masimo Corporation (MASI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SET and rainbow SET technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest available reporting period.